12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

SARcode, Shire deal

Shire will acquire SARcode for $160 million up front, plus undisclosed milestones. Shire will gain SARcode's lifitegrast, an eye drop formulation of a small molecule integrin beta(2) (LFA-1; MAC-1; CD18) antagonist in Phase III testing to treat signs and symptoms of dry eye. Shire said it is conducting...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >